Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies

References

• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 May;20(5):533–13. doi:10.1016/S1473-3099(20)30120-1.
   PubMed Web of Science ®Google Scholar
• Yimer B, Ashebir W, Wolde A, Teshome M. COVID-19 and Global Health Security: overview of the Global Health Security Alliance, COVID-19 response, African countries’ approaches, and ethics. Disaster Med Public Health Prep. 2020 Oct;2:1–5. doi:10.1017/dmp.2020.360.
   Google Scholar
• Katz LM. A little clarity on convalescent plasma for Covid-19. N Engl J Med. 2021 Feb 18;384(7):666–68. doi:10.1056/NEJMe2035678.
   PubMed Web of Science ®Google Scholar
• Ali MG, Zhang Z, Gao Q, Pan M, Rowan EG, Zhang J. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. Immunol Res. 2020 Dec;68(6):325–39. doi:10.1007/s12026-020-09159-z.
   PubMed Web of Science ®Google Scholar
• Jiang S, Zhang X, Yang Y, Hotez PJ, Du L. Neutralizing antibodies for the treatment of COVID-19. Nat Biomed Eng. 2020 Dec;4(12):1134–39. doi:10.1038/s41551-020-00660-2.
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576–88. doi:10.1002/psp4.12224.
   PubMedGoogle Scholar
• Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 2020 Aug 1;5847821:443–49. doi:10.1038/s41586-020-2548-6.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238–51. doi:10.1056/NEJMoa2035002.
   PubMed Web of Science ®Google Scholar
• Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):229–37. doi:10.1056/NEJMoa2029849.
   PubMed Web of Science ®Google Scholar
• Mitchell LS, Colwell LJ. Comparative analysis of nanobody sequence and structure data. Proteins. 2018 Jul;86(7):697–706. doi:10.1002/prot.25497.
   PubMed Web of Science ®Google Scholar
• Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007 Nov;77(1):13–22. doi:10.1007/s00253-007-1142-2.
   PubMed Web of Science ®Google Scholar
• Bannas P, Hambach J, Nanobodies K-NF. Nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol. 2017;8:1603–1603. doi:10.3389/fimmu.2017.01603.
   PubMed Web of Science ®Google Scholar
• Grant OC, Montgomery D, Ito K, Woods RJ. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Sci Rep. 2020 Sep 14;10(1):14991. doi:10.1038/s41598-020-71748-7.
   PubMed Web of Science ®Google Scholar
• Wilton EE, Opyr MP, Kailasam S, Kothe RF, Wieden H-J. sdAb-DB: the Single Domain Antibody Database. ACS Synth Biol. 2018 Nov 16;7(11):2480–84. doi:10.1021/acssynbio.8b00407.
   PubMed Web of Science ®Google Scholar
• Moutel S, Bery N, Bernard V, Keller L, Lemesre E, de Marco A, Ligat L, Rain JC, Favre G, Olichon A, et al. NaLi-H1: a universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. Elife. 2016;19;5:e16228.
   Web of Science ®Google Scholar
• Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, Bloyet LM, Zeng Q, Tahan S, Droit L, et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host & Microbe. 2020 2020/09/09/;28(3):475-485.e5.
   Google Scholar
• Dong J, Huang B, Wang B, Titong A, Gallolu Kankanamalage S, Jia Z, Wright M, Parthasarathy P, Liu Y. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2. Sci Rep. 2020 Oct 20;10(1):17806. doi:10.1038/s41598-020-74761-y.
   PubMed Web of Science ®Google Scholar
• Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE, Earnest JT, Keeler SP, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020 Nov;21(11):1327–35. doi:10.1038/s41590-020-0778-2.
   PubMed Web of Science ®Google Scholar
• What is the economic cost of covid-19? The Economist. 2021 Jan 7, 2021.
   Google Scholar
• FDA authorizes revisions to fact sheets to address SARS-CoV-2 variants for monoclonal antibody products under emergency use authorization [Internet]. U.S. Food & Drug Administration; 2021; Mar 10, 2021;[1]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-fact-sheets-address-sars-cov-2-variants-monoclonal-antibody-products-under
   Google Scholar
• Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020 Aug 21;369(6506):1014–18. doi:10.1126/science.abd0831.
   PubMed Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D, Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009 Jun 30; received Sep 1; revised 01/12/accepted;1572:220–33. doi:10.1111/j.1476-5381.2009.00190.x.
   PubMed Web of Science ®Google Scholar
• Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020 Jun 2;16(6):1232–38. doi:10.1080/21645515.2020.1735227.
   PubMed Web of Science ®Google Scholar
• Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature.2020/08/01;584(7819):115-119.
   Google Scholar
• Schoof M, Faust B, Saunders RA, Sangwan S, Rezelji V, Hoppe N, Boone M, Billesbolle CB, Puchades C, Azumaya CM, et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020 Dec 18;370(6523):1473–79.
   PubMed Web of Science ®Google Scholar
• Li W, Schäfer A, Kulkarni SS, Liu X, Martinez DR, Chen C, Sun Z, Leist SR, Drelich A, Zhang L, et al. High potency of a bivalent human V(H) domain in SARS-CoV-2 animal models. Cell. 2020 Oct 15;183(2):429–41. e16. doi:10.1016/j.cell.2020.09.007.
   PubMed Web of Science ®Google Scholar
• Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Scheuplein F, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol. 2009 Aug;198(3):157–74. doi:10.1007/s00430-009-0116-7.
   PubMed Web of Science ®Google Scholar
• Huo J, Le Bas A, Ruza RR, Duyvesteyn HME, Mikolajek H, Malinauskas T, Tan TK, Rijal P, Dumoux M, Ward PN, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020 2020 Sep 1;279:846–54. doi:10.1038/s41594-020-0469-6.
   PubMed Web of Science ®Google Scholar
• Koenig P-A, Das H, Liu H, Kümmerer BM, Gohr FN, Jenster L-M, Schiffelers LDJ, Tesfamariam YM, Uchima M, Wuerth JD, et al. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science. 2021;371(6530):eabe6230. doi:10.1126/science.abe6230.
   PubMed Web of Science ®Google Scholar
• Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L, Hoffmann M, Pöhlmann S, et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell. 2020;181(5):1004–1015.e15. doi:10.1016/j.cell.2020.04.031.
   PubMed Web of Science ®Google Scholar
• Bracken CJ, Lim SA, Solomon P, Rettko NJ, Nguyen DP, Zha BS, Schaefer K, Byrnes JR, Zhou J, Lui I, et al. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. Nat Chem Biol. 2021 Jan;17(1):113–21. doi:10.1038/s41589-020-00679-1.
   PubMed Web of Science ®Google Scholar
• Sun Z, Chen C, Li W, Martinez DR, Drelich A, Baek D-S, Liu X, Mellors JW, Tseng C-T, Baric RS et al. Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold. MAbs. 2020 Jan 1;12(1):1778435. doi:10.1080/19420862.2020.1778435.
   PubMed Web of Science ®Google Scholar
• Lu Q, Zhang Z, Li H, Zhong K, Zhao Q, Wang Z, Wu Z, Yang D, Sun S, Yang N, et al. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. J Nanobiotechnology. 2021 2021 Jan 29;191:33. doi:10.1186/s12951-021-00768-w.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Nambulli S, Xiao Z, Liu H, Sang Z, Duprex PW, Schneidman-Duhovny D, Zhang C, Shi Y. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science. 2020;370(6523):1479–84.
   PubMed Web of Science ®Google Scholar
• Sia SF, Yan L-M, Chin AWH, Fung K, Choy K-T, Wong AYL, Kaewpreedee P, Perera RAPM, Poon LLM, Nicholls JM, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020 2020 Jul 1;5837818:834–38. doi:10.1038/s41586-020-2342-5.
   PubMed Web of Science ®Google Scholar
• Dinnon KH 3rd, Leist SR, Schäfer A, Edwards CE, Martinez DR, Montgomery SA, West A, Yount BL, Hou YJ, Adams LE, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020 Oct;586(7830):560–66. doi:10.1038/s41586-020-2708-8.
   PubMed Web of Science ®Google Scholar
• Rosenfeld R, Noy-Porat T, Mechaly A, Makdasi E, Levy Y, Alcalay R, Falach R, Aftalion M, Epstein E, Gur D, et al. Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody. Nat Commun. 2021 2021 Feb 11;121:944. doi:10.1038/s41467-021-21239-8.
   PubMed Web of Science ®Google Scholar
• Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, Zost SJ, Jang H, Huang Y, Allen JD, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021 2021 Apr 1. 1847:1804–20. e16. doi:10.1016/j.cell.2021.02.026
   PubMed Web of Science ®Google Scholar
• Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, et al. 2021. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell. 2021 Feb 23. 184(9):2348-2361.e6
   Web of Science ®Google Scholar
• Tchesnokova V, Kulakesara H, Larson L, Bowers V, Rechkina E, Kisiela D, Sledneva Y, Choudhury D, Maslova I, Deng K, et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. bioRxiv. 2021 2021 Feb 22. 432189.
   Google Scholar
• Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E. Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA. 2021;325(13):1324. doi:10.1001/jama.2021.1612.
   PubMed Web of Science ®Google Scholar
• Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-Gonzalez A, Glasner DR, Reyes KR, Gliwa AS, Reddy NP, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv. 2021Mar 7;21252647.
   Google Scholar
• Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Maison RM, Gazumyan A, Martinez DR, et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med. 2020;218:3.
   Web of Science ®Google Scholar
• Liu R, Oldham RJ, Teal E, Beers S, Cragg M. Fc-engineering for modulated effector functions—Improving antibodies for cancer treatment. Antibodies. 2020;9(4):64. doi:10.3390/antib9040064.
   Web of Science ®Google Scholar
• van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease [Review]. Front Immunol. 2019 2019 March 22;10(548). doi:10.3389/fimmu.2019.00548.
   PubMedGoogle Scholar
• Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260–63. doi:10.1126/science.abb2507.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018 Sep 1;34(17):i884–i890. doi:10.1093/bioinformatics/bty560.
   PubMed Web of Science ®Google Scholar
• Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc. 2007;2(9):2212–21. doi:10.1038/nprot.2007.321.
   PubMed Web of Science ®Google Scholar
• Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, Liu J, Schindewolf C, Bopp NE, Aguilar PV, et al. An Infectious cDNA clone of SARS-CoV-2. Cell Host Microbe. 2020;27(5):841–848.e3. doi:10.1016/j.chom.2020.04.004.
   PubMed Web of Science ®Google Scholar
• Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012 Mar 4;9(4):357–59. doi:10.1038/nmeth.1923.
   PubMed Web of Science ®Google Scholar
• Robinson JT, Thorvaldsdóttir H, Wenger AM, Zehir A, Mesirov JP. Variant review with the integrative genomics viewer. Cancer Res. 2017 Nov 1;77(21):e31–e34. doi:10.1158/0008-5472.CAN-17-0337.
   PubMed Web of Science ®Google Scholar